Table 1 |. Radiotracers and details of accrual for IRB 17–538 specifying range of radiotracer administered and number of patient imaging sessions accrued at the time of writing.
Details reflect range of administered activity to the patient and computed Cerenkov light based on (43,53).
| Radio-pharmaceutical | Indication | Clinical imaging mode | Typical dose, mCi (GBq) |
Cerenkov light generated by isotope (photons/decay)43,53 |
Total possible Cerenkov light at injection (photons/second) × 109 |
Number of patient imaging sessions |
|---|---|---|---|---|---|---|
| Na131I | Thyroid cancer adjuvant therapy | SPECT | 27–200 (1.0–7.4) |
0.669 | 5.0 | 25 |
| 18F-FDG | General disease staging | PET | 10–14.9 (0.37–0.55) |
1.32 | 0.7 | 20 |
| 68Ga-DOTATATE | Neuroendocrine PET imaging | PET | 4.4–5.5 (119–149) |
33.9 | 6.3 | 28 |
| 177Lu-DOTATATE | Neuroendocrine radiotherapy | SPECT | 188–200 (6.9–7.4) |
0.141 | 1.0 | 26 |
| 223RaCl2 | Metastatic castration-resistant prostate cancer therapy | None (separate PET or SPECT scan) | 0.091–0.177 (0.0033–0.0065) |
28.0104 (with daughters) |
0.2 | 7 |